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Digital Health Support in Treatment for Tuberculosis
To the Editor: Improving support for patients 
with tuberculosis is a major priority for govern-
ments and development agencies.1 Digital health 
interventions have the potential to address short-
falls in the current standard of care.2 Although 
access to the Internet, smartphones, and other 
forms of technology is still limited in areas with 
a high tuberculosis burden, mobile “feature” 
phones (i.e., phones that lack the advanced func-
tionality of smartphones but can be used to make 
calls, send text messages, and access some simple 
Internet features through a text-based interface) 
are ubiquitous.3 We therefore developed a digital 
health platform that was compatible with feature 
phones to provide support for patients with tuber-
culosis.
Each day, patients received a text message 
asking them to verify adherence to treatment. 
Such interactive messaging approaches have 
shown more promise for promoting adherence 
than one-way reminders.4 If the patient did not 
verify adherence, two additional messages were 
sent to the patient at 1-hour intervals, followed 
by messages and then phone calls from study 
team members who had personal experience of 
successful completion of treatment for tubercu-
losis; if there was still no response, a notifica-
tion was sent to the clinic. This approach en-
sured that nonadherence was addressed in a 
timely fashion and presented patients with a re-
source for overcoming barriers such as challenges 
in accessing care, stigma in the community, and 
lack of information, motivation, or support. It 
also made patients feel accountable to others for 
their adherence or nonadherence; social science 
research suggests that such accountability moti-
vates cooperative behavior.5
The digital health platform also provided infor-
mation about tuberculosis. Weekly motivational 
messages such as “Taking your pills will help 
you get better and keep you from infecting fam-
ily and friends” were sent by text message, and 
patients participated in an “adherence contest” 
in which they could compare their reported ad-
herence with that of others and could qualify for 
a “winner’s circle” if their adherence was 90% or 
higher. These features further enhanced account-
ability, helped to establish a norm of adherence, 
and emphasized the benefits of adherence in the 
community — all of which motivated patients to 
cooperate.5 All platform content was developed 
in conjunction with local study team members 
to ensure that it would be comprehended by and 
appropriate for the study population.
To determine whether this platform would 
result in a better frequency of treatment success 
when it was combined with the standard of care, 
we collaborated with 17 clinics in Nairobi to per-
form an individual-level, parallel, randomized, 
controlled trial (Tables S1 through S3 in the 
Supplementary Appendix, available with the full 
text of this letter at NEJM.org). The primary 
trial outcome was an unsuccessful treatment 
outcome, which was defined as a composite of 
death during treatment for tuberculosis, treat-
ment failure (i.e., the patient’s sputum smear or 
culture was positive at month 5 or later), or loss 
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to follow-up (i.e., the patient interrupted treat-
ment for ≥2 consecutive months).
The trial was approved by the institutional 
review board of Kenyatta National Hospital and 
the University of Nairobi. Trial patients or their 
parents or guardians provided written informed 
consent. Details about the methods are provided 
in the Supplementary Appendix and the protocol 
and statistical analysis plan, available at NEJM 
.org; ClinicalTrials.gov number, NCT03135366.
After exclusion of patients who had received 
a misdiagnosis or were transferred out of their 
clinic, 1104 patients remained: 535 in the control 
group and 569 in the intervention group. Of these 
patients, unsuccessful treatment outcomes oc-
curred in 70 patients (13.1%) in the control group 
and 24 patients (4.2%) in the intervention 
group (P<0.001) (Fig. 1). The results in the two 
groups were similarly large and significant when 
only loss to follow-up was considered, when only 
patients with bacteriologically confirmed infec-
tion were included, or after adjustment for indi-
vidual characteristics (Tables S5 and S6 in the 
Supplementary Appendix). Our results suggest 
that interventions delivered with feature phones 
can help to address shortfalls in the current 
standard of care for patients with tuberculosis.
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Figure 1. Unsuccessful Treatment Outcomes, According 
to Trial Group.
An unsuccessful outcome of treatment for tuberculosis 
was defined as any of the following: death during treat-
ment, treatment failure (the patient’s sputum smear or 
culture was positive at month 5 or later), or loss to follow-
up (the patient did not start treatment or interrupted 
treatment for ≥2 consecutive months). A total of 535 
patients in the control group received the standard of 
care, whereas 569 patients in the intervention group 
received treatment support through a digital health 
platform. A total of 13.1% of patients in the control 
group (70 patients) had unsuccessful treatment out-
comes, as compared with 4.2% of patients in the inter-
vention group (24 patients) (P<0.001). I bars indicate 
standard errors.
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